Trial Overview

Biogen Inc. (NASDAQ:BIIB) reported results from its Phase 2 CELIA study of the tau‑targeting Alzheimer’s therapy diranersen. While the molecule achieved a landmark 50%‑65% reduction in cerebrospinal‑fluid total tau and significant clearance of brain tau pathology across all dose arms, it failed to meet the primary endpoint of demonstrating a dose‑dependent response on the Clinical Dementia Rating‑Sum of Boxes (CDR‑SB).

Efficacy by Dose

The study evaluated three dosing regimens: 60 mg administered every six months, 115 mg every six months, and 115 mg every three months. The 60 mg arm produced a 26% slowing of CDR‑SB decline, a 42% improvement on the ADAS‑Cog13 cognitive test, and a 50% gain on the MMSE mental‑state exam. In contrast, the 115 mg every‑six‑months arm showed only a 14% CDR‑SB slowing, 32% ADAS‑Cog13 improvement, and 34% MMSE gain, while the 115 mg every‑three‑months arm recorded 9% CDR‑SB slowing, 29% ADAS‑Cog13 improvement, and 38% MMSE gain.

Safety Profile

Diranersen was notable for a 0% incidence of amyloid‑related imaging abnormalities (ARIA), a safety advantage compared with existing anti‑amyloid agents such as Leqembi and Kisunla, which exhibit real‑world ARIA rates around 10%. Serious adverse events in the 60 mg cohort were comparable to placebo at 13%. However, the higher‑dose arms experienced substantial discontinuation rates of 20%‑25% due to severe procedure‑related pain and confusional states.

Biomarker and Mechanistic Highlights

The therapy, which knocks down MAPT mRNA, is the first to demonstrate a robust 50%‑65% reduction in CSF total tau alongside consistent reductions in brain tau pathology across all dosing levels. This biomarker success, combined with the clean ARIA profile, positions diranersen as a potentially superior approach to extracellular‑targeting monoclonal antibodies.

Analyst Reactions

Morgan Stanley analyst Terence Flynn noted that the 60 mg efficacy landed at the lower end of expectations and emphasized management’s inability to explain the inverse dose response as the main driver of the stock’s weakness. William Blair’s Myles Minter acknowledged the modest efficacy but argued that the data validates the hypothesis that intracellular tau knock‑down is the correct therapeutic path, suggesting superiority over monoclonal antibody approaches. Jefferies analyst Andrew Tsai took a more optimistic view, stating that the 26% slowing observed with the 60 mg dose aligns with the 23%‑27% slowing reported for Leqembi and Kisunla, and hypothesized an optimal “ceiling” for tau reduction.

Market Impact

Following the release of the data, Biogen’s shares declined approximately 8.7% (ticker showing an 8.47% drop), reflecting investor concern over the dosing paradox and the missed primary endpoint despite the strong biomarker and safety signals. Management now faces pressure to resolve the dosing mystery and refine patient selection criteria before proceeding to a Phase 3 trial.